TRVI

Company Overview — What Does Trevi Therapeutics, Inc. Do?

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. Trevi Therapeutics, Inc. (TRVI) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jennifer L. Good and employs approximately 20 people. With a market capitalization of $1.5B, TRVI is one of the notable companies in the Healthcare sector.

Trevi Therapeutics, Inc. (TRVI) Stock Rating — Reduce (April 2026)

As of April 2026, Trevi Therapeutics, Inc. receives a Reduce rating with a composite score of 36.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.TRVI ranks #2,506 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Trevi Therapeutics, Inc. ranks #321 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TRVI Stock Price and 52-Week Range

Trevi Therapeutics, Inc. (TRVI) currently trades at $13.19. The stock lost $0.11 (0.8%) in the most recent trading session. The 52-week high for TRVI is $14.39, which means the stock is currently trading -8.3% from its annual peak. The 52-week low is $4.85, putting the stock 172.0% above its annual trough. Recent trading volume was 974K shares, suggesting relatively thin trading activity.

Is TRVI Overvalued or Undervalued? — Valuation Analysis

Trevi Therapeutics, Inc. (TRVI) carries a value factor score of 34/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 8.86x, versus the sector average of 2.75x.

At current multiples, Trevi Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Trevi Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Trevi Therapeutics, Inc. (TRVI) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -25.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -23.9% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TRVI Debt, Balance Sheet, and Financial Health

Trevi Therapeutics, Inc. has a debt-to-equity ratio of 5.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 21.93x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $57M.

TRVI has a beta of 0.62, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Trevi Therapeutics, Inc. is 50/100, reflecting average volatility within the normal range for its sector.

Trevi Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Trevi Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.08. Net income for the quarter was $-48M. Operating income came in at $-53M.

In Q3 2025, Trevi Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.08. Net income for the quarter was $-12M. Operating income came in at $-14M.

In Q2 2025, Trevi Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.09. Net income for the quarter was $-12M. Operating income came in at $-14M.

In Q1 2025, Trevi Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.09. Net income for the quarter was $-10M. Operating income came in at $-11M.

Over the past 8 quarters, Trevi Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing TRVI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TRVI Dividend Yield and Income Analysis

Trevi Therapeutics, Inc. (TRVI) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TRVI Momentum and Technical Analysis Profile

Trevi Therapeutics, Inc. (TRVI) has a momentum factor score of 63/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 2/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

TRVI vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Trevi Therapeutics, Inc. (TRVI) ranks #321 out of 838 stocks based on the Blank Capital composite score. This places TRVI in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TRVI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TRVI vs S&P 500 (SPY) comparison to assess how Trevi Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

TRVI Next Earnings Date

No upcoming earnings date has been announced for Trevi Therapeutics, Inc. (TRVI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TRVI? — Investment Thesis Summary

The quantitative profile for Trevi Therapeutics, Inc. suggests caution. The quality score of 25/100 flags below-average profitability. The value score of 34/100 indicates premium valuation. Price momentum is positive at 63/100, suggesting the trend favors buyers.

In summary, Trevi Therapeutics, Inc. (TRVI) earns a Reduce rating with a composite score of 36.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TRVI stock.

Related Resources for TRVI Investors

Explore more research and tools: TRVI vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TRVI head-to-head with peers: TRVI vs AZN, TRVI vs SLGL, TRVI vs VMD.